The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
© Wiiger et al.; licensee BioMed Central Ltd. 2014
Received: 25 September 2013
Accepted: 11 February 2014
Published: 15 February 2014
The standard treatment of ovarian cancer with chemotherapy often leads to drug resistance and relapse of the disease, and the need for development of novel therapy alternatives is obvious. The MOC31PE immunotoxin binds to the cell surface antigen EpCAM, which is expressed by the majority of epithelial cancers including ovarian carcinomas, and we studied the cytotoxic effects of MOC31PE in ovarian cancer cells.
Investigation of the effects of MOC31PE treatment on protein synthesis, cell viability, proliferation and gene expression of the ovarian cancer cell lines B76 and HOC7.
MOC31PE treatment for 24 h caused a dose-dependent reduction of protein synthesis with ID50 values of less than 10 ng/ml, followed by reduced cell viability. In a gene expression array monitoring the expression of 84 key genes in cancer pathways, 13 of the genes were differentially expressed by MOC31PE treatment in comparison to untreated cells. By combining MOC31PE and the immune suppressor cyclosporin A (CsA) the MOC31PE effect on protein synthesis inhibition and cell viability increased tenfold. Cell migration was also reduced, both in the individual MOC31PE and CsA treatment, but even more when combining MOC31PE and CsA. In tumor metastasis PCR arrays, 23 of 84 genes were differentially expressed comparing CsA versus MOC31PE + CsA treatment. Increased expression of the tumor suppressor KISS1 and the nuclear receptor NR4A3 was observed, and the differential candidate gene expression was confirmed in complementary qPCR analyses. For NR4A3 this was not accompanied by increased protein expression. However, a subcellular fractionation assay revealed increased mitochondrial NR4A3 in MOC31PE treated cells, suggesting a role for this protein in MOC31PE-induced apoptotic cell death.
The present study demonstrates that MOC31PE may become a new targeted therapy for ovarian cancer and that the MOC31PE anti-cancer effect is potentiated by CsA.
Ovarian cancer is the leading cause of death from gynecological cancers and the patients are commonly diagnosed late with advanced disease. In general, the patients respond well to the primary treatment involving cytoreductive surgery and chemotherapy. However, more than 70% of the patients relapse, and in the recurrent disease, resistance to chemotherapeutic drugs is common[1, 2]. New targeted therapies are under evaluation, and immunotoxins (ITs) may represent an interesting alternative. ITs consist of an antibody, that with high affinity binds to the target antigen on the cancer cell surface, and a covalently bound toxin. Our MOC31PE immunotoxin binds to the cell surface antigen EpCAM, which is expressed by the majority of epithelial cancers including ovarian carcinomas. Upon internalisation Pseudomonas exotoxin A (PE) inhibits protein synthesis by ADP-ribosylation of elongation factor 2 and induces apoptosis. EpCAM is a transmembrane glycoprotein, functioning as an epithelial-specific cell-cell adhesion molecule and may be involved in cellular signaling, migration, proliferation, and differentiation. Recently, it has been suggested that EpCAM is a cancer stem cell marker and may be expressed by cells undergoing epithelial to mesenchymal transition (EMT), lacking other epithelial markers. EMT-like cellular processes may be important during cancer metastasis, and EpCAM is thus an excellent candidate for therapeutic targeting of epithelial cancers. In a retrospective study of 500 ovarian cancer patients, EpCAM showed consistently high expression across different tumor stages and subtypes and the protein was over-expressed in cancerous tissues compared with non-cancerous ovarian surface epithelium and inclusion cysts. Notably, MOC31PE also induces cell death in chemotherapy-resistant cancer cells and may hence be used in patients with recurrent disease lacking other therapeutic options.
The immune suppressor cyclosporin A (CsA) was introduced in combination with IT to inhibit the host immune response during repeated IT administrations. In parallel with reduced anti-IT antibody production, synergistic cytotoxic effects were observed in vitro and in vivo. The immunosuppressive effect of CsA is caused by binding to cyclophilin A (CypA). This complex binds and inhibits calcineurin a key enzyme for IL-2 production in T-cells. CypA over-expression has been reported in many human cancers and has also been suggested as a potential therapeutic target. Interestingly, CsA has been reported to reverse chemotherapeutic resistance in patients with recurrent ovarian cancer[11, 12]. In the present work, we have studied the effects of MOC31PE treatment alone and in combination with CsA on protein synthesis, cell proliferation, viability, and migration on the ovarian cancer cell lines B76 and HOC7, which both express high amounts of EpCAM. Furthermore, MOC31PE-induced alterations in gene transcription were quantified in two different PCR-arrays: Cancer Pathway Finder and Tumor Metastasis.
Materials and methods
RPMI-1640, PBS, Glutamax, and Hepes were obtained from Lonza (Austria). Fetal calf serum was purchased from PAA (GE Healthcare, UK), MEM w/o leucine, 0.25% Trypsin/EDTA from Gibco, and YoYo-1 fluorescent dsDNA staining from Molecular Probes (Life Technologies, UK), and tritiated Leucine from Perkin Elmer (Waltham, MA). Cyclosporine A was purchased from Calbiochem (San Diego, CA) and dissolved in ethanol to 8.3 mM stock solution. The GenElute Mammalian total RNA kit and general laboratory chemicals were from Sigma Aldrich (St. Louis, MO), the Cell Titer 96 AqueousOne solution (MTS) cell proliferation assay was from Promega (Madison, WI). RT2 Profiler PCR Array System, including the cDNA synthesis kit, and SYBR green were from SABiosciences (Qiagen Nordic). Chemicals for validation of gene expression were from Applied (Life Technologies, UK). Plastic ware for cell culture was from Nunc (Thermo Scientific), gels and buffers for protein electrophoresis from Life Technologies, HRP-conjugated antibodies from Dako (DK), and chemiluminescent super-signal substrate from Thermo Scientific.
Cells and immunotoxin
The human ovarian cancer cell lines B76 and HOC-7 were a gift from Dr C. Marth (Innsbruck Medical University, Innsbruck, Austria). In this study B76 was our main cell line and HOC-7 was used to confirm key results. The cell lines were cultivated in RPMI 1640 medium added Glutamax, Hepes and 8% heat-inactivated fetal calf serum. The monoclonal antibody MOC31 binds epithelial cell adhesion molecule (EpCAM, CD326) and was conjugated to whole Pseudomonas exotoxin A as previously described.
Protein synthesis and cell viability
Cell proliferation, membrane damage and scratch-wound healing in the IncuCyte
Cells were seeded in 96 well plates and grown to ≈ 50% confluency, transferred to the IncuCyte (Essen BioSciences, Ann Arbor, Mi) after the medium was replaced with fresh medium with or without IT and/or CsA. Membrane damage was measured after adding YoYo-1, a dye that emit fluorescence when it binds to double-stranded DNA. The cytotoxic index is defined as the number of fluorescent objects in a well, divided by the total number of fluorescent objects obtained after 0.1% Triton X-100 is added to open all cells in the well. For migration studies, the wound maker tool was used to make scratch wounds in confluent cell culture monolayers in 96 well image-lock plates (Essen BioSciences). Plates were incubated in the IncuCyte for 24 h and an integrated metric called relative wound density (RWD) was used to quantify effects on migration. This metric measures the cell density in the wound area relative to the cell density outside the wound area.
RNA isolation and PCR array analyses
The cells were seeded in 6 well plates, grown to ≈ 80% confluency and treated for 24 h before RNA was isolated from adherent cells using the GenElute Mammalian total RNA kit (Sigma Aldrich) and quantified in a Picodrop spectrophotometer (Picodrop Ltd, UK). RNA isolated for PCR array assays was treated with DNase I (Invitrogen) and the RNA quality was checked in the UV spectrophotometer. For cDNA synthesis (1 μg/reaction) the RT2 first strand kit from SABiosciences was used. The resulting cDNA was diluted and qPCR was run as described in the PCR array protocol (SABiosciences RT2 Profiler PCR Array System) using a BioRad ICycler. Gene expression was tested using either Cancer Pathway Finder (untreated, IT 10 ng/ml) - or Tumor Metastasis (2 μM CsA, CsA + IT 10 ng/ml) array. There are primers for 84 test genes and 5 reference genes (B2M, HPRT1, RPL13A, GAPDH, and ACTB) on each 96-well plate. Data analysis was performed as described in the protocol from the manufacturer and by using their PCR Array Data Analysis Web portal (http://www.SABiosciences.com).
Validation of PCR array data
Gene expression was validated in independent experiments with RNA isolated as described above. The high capacity RNA to DNA master mix was used for cDNA synthesis (1 μg RNA/ reaction). Gene expression was measured using qPCR analyses with TaqMan probes using the 7500 Real Time PCR machine (Applied Biosystems). Each sample was tested in duplicate. Fold change in expression was calculated using the comparative Ct method with RPL37A as a reference gene since the expression of this gene was similar in control and experimental groups. The gene list and corresponding probes are shown in Additional file1: Table S1.
Subcellular fractionation, gel electrophoresis, and antigen detection
Cells were grown to 70-80% confluency in 75 cm2 flasks and treated with MOC31PE and/or CsA for 24 h. The cells were washed with cold PBS and lysed in 500 μl SF buffer (250 mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA and 1 mM EGTA, pH 7.5) and the protease inhibitor cocktail was added (MiniComplete, Roche). Cells were scraped from the flasks and the lysates were passed through 25G needles 10 times, and incubated on ice for 20 min. The nuclear pellet was centrifuged out at 720 g for 5 min and the resulting supernatant centrifuged at 10000 g for 10 min to separate the cytosolic (supernatant) and mitochondrial (pellet) fractions. Pellets were washed with 500 μl SF buffer, passed through 25G needles 10 times and re-centrifuged. Finally, the pellets were resuspended in 50 μl lysis buffer (10 mM Tris pH 7.5, 1% SDS, 1 mM Na3VO4, 0.1% Triton X-100, and 10% glycerol) and briefly sonicated. For total cell lysates, cells were lysed in boiling lysis buffer as previously described. Proteins were resolved on 4-12% Nu-PAGE gels and blotted onto PVDF membranes for antigen detection. The purity of the fractions was validated with antibodies detecting α-tubulin (cytosol, Cell Signaling), lamin B1 (nucleus, Abcam), and F1F0-ATP synthase (mitochondria, Calbiochem). NR4A3 in the fractions was detected on separate blots using a polyclonal anti-NR4A3/NOR-1 antibody (Novus Biologicals). Chemiluminescence signals were recorded using the G:Box system with a CCD camera from SynGene and quantified using the provided GeneTool software.
Statistical significance was evaluated with two-tailed Students t-test except for qPCR validations where non-parametric Mann–Whitney tests were used. In both tests p-values at 0.05 were considered statistically significant.
MOC31PE immunotoxin inhibits protein synthesis and reduces cell viability
MOC31PE immunotoxin induces cell membrane damage and reduces cell migration
Effects of MOC31PE immunotoxin on gene expression
Fold change in gene expression comparing control (untreated cells) and 10 ng/ml IT treated B76 cells
Fibroblast growth factor receptor 2
Tumor necrosis factor
Platelet derived growth factor β
Cell cycle control and DNA damage repair
CDC25 phosphatase family
Cyclin dependent kinase inhibitor
Signal transduction molecules and transcription factors
Epidermal growth factor receptor family
Using qPCR, possible effects of CsA alone and in combination with IT on expression of THBS1 and PDGFβ were also investigated. In CsA treated cells the expression of THBS1 and PDGFβ was two-fold reduced (n = 2) compared to the expression in untreated control cells. In four independent experiments, the combination treatment compared to CsA alone treatment gave median fold changed expression of 34.5 (from 4.4 to 76.3, p < 0.05) for THBS1 and of 13.9 for PDGFβ (4.5 to 41.3, p < 0.05).
Fold change in gene expression comparing CsA treated B76 cells with or without 10 ng/ml IT
Pinin, desmosome-associated protein
Cadherin-related tumor suppressor homolog
Breast cancer metastase suppressor, transcriptional repressor
Cell cyclus and transcription factor
Retinoblastoma, tumor suppressor, transcriptional repressor
Tumor suppressor, transcription factor
Cell cyclus or cell proliferation
Expressed in Non-Metastatic cells, nucleoside diphosphate kinase
Cell growth and proliferation
Somatostatin receptor 2, ligand somatostatin 14/28
Density-regulated protein, involved in translation
Receptor for KISS1
Receptor tyrosine kinase, ligand VEGF C/D
CXC chemokine receptor, ligand SDF-1
Receptor tyrosine kinase, ligand ephrin-family members
Cathepsin K, cysteine protease
Expressed in Non-Metastatic cells, nucleoside diphosphate kinase
SMAD family member,
Nuclear-receptor subfamily 4 member A3, potential transcriptional activator
Effects of MOC31PE immunotoxin on NR4A3 protein expression and subcellular localization
The major limitation to curative therapy for ovarian cancer is acquired drug resistance to the chemotherapeutic agents used, such as Carboplatin and Paclitaxel. An additional drawback is the induced severe side-effects, mainly caused by the non-cancer cell specificity of the agents, reducing the patients’ quality of life. It is therefore necessary to identify novel drugs, which circumvent these disadvantages for successful treatment of ovarian cancer. In the present study, we have demonstrated in several different assays that the MOC31PE effectively inhibits protein synthesis, proliferation and cell survival of ovarian cancer cells, B76 and HOC7. Previously, we have reported in other tumor types synergistic cytotoxic effects of combining MOC31PE and CsA in vitro and in an experimental metastasis model in animals. In agreement with previous results in other tumor types, these effects are potentiated when cells are simultaneously exposed to the immunosuppressant CsA.
The MOC31PE only binds to and kill cells expressing the antigen EpCAM, which is expressed in more than 90% of all epithelial ovarian carcinomas and to a negligible amount on normal cells, reducing the possibility of IT induced side effects in patients. In a recently conducted Phase I clinical study with MOC31PE, the tolerable profile was satisfactory (Andersson et al., in preparation), which is encouraging for clinical evaluation of MOC31PE against ovarian carcinoma. Interestingly, Phase I and II trials with CsA have shown beneficial effects on chemoresistance in patients with ovarian cancer[11, 20] indicating that the combination of MOC31PE and CsA could be used for recurrent ovarian cancer.
Gene expression analysis was performed to identify affected signaling pathways induced by the treatments and several interesting candidate genes were found. In the Cancer Pathway Finder array, the majority of the genes affected by MOC31PE were related to angiogenesis, reflecting the importance of this cancer pathway in B76 cell growth. The two genes with the highest fold increase in expression on the array, PDGFβ and THBS1, was confirmed by qPCR. The PDGF network was recently identified as a biomarker for prognosis in ovarian cancer where higher levels of PDGF pathway activity were associated with reduced survival. The angiogenesis inhibitor Bevacizumab (Avastin), that binds to VEGF A, is an used molecular target agent in ovarian cancer. Given the importance of the PDGF pathway, targeting of VEGF, PDGF, and FGF at the same time may be more effective than targeting only VEGF. THBS1 was the first endogenous angiogenesis inhibitor identified. A role in cancer progression and cancer inhibition has been ascribed to the protein, and different effects of THBS1 depending on the phase of the progression have been suggested. In an early stage, high stromal expression of THBS1 inhibits tumor growth whereas later in the vascularized tumor THBS1 may increase the adhesive properties of tumor cells or modulate extracellular matrix proteins thereby promoting tumor invasion. We observed that CsA mono-treatment inhibited migration and reduced expression of some transcripts, including THBS1 in addition to potentiating IT effects. Calcineurin, the phosphatase inhibited by CsA, has been reported to regulate transcription of CTSK and CXCR4; two of five other affected genes. The inhibition of B76 cell migration by IT + CsA treatment may be a result of reduced THBS1 and/or MMP9 protein levels since increased transcription cannot be accompanied by increased translation due to IT-induced protein synthesis inhibition. In the tumor metastasis array mainly increased gene expression was seen when comparing CsA alone versus CsA + MOC31PE treatment of B76 cells. Examples of genes influenced are the metastasis suppressor KISS1 and its receptor. In ovarian carcinoma the increased expression of KISS1 has been shown to inhibit cell migration. This might support the results from the scratch-wound healing assay showing decreased migration in the B76 cells treated with MOC31PE alone or MOC31PE + CsA. Higher expression of KISS1 may also sensitize cancer cells for chemotherapy. Thus our results might support a contribution of MOC31PE as a supplement also to reduce chemotherapy resistance in ovarian cancer treatment.
The largest up-regulation was observed for the nuclear hormone receptor NR4A3, a member of the NR4A subfamily with poorly understood biological function and unknown physiological ligands. Depending on the context, NR4A transcription factors may be pro-survival factors or induce cell death. Knock-out mice without NR4A3 (Nor-1) and NR4A1 (Nur77) developed spontaneous acute myeloid leukemia suggesting tumor suppressing effects. In cancer cells, growth factors and mitogens induce expression of these transcription factors suggesting a role in cancer growth. However, induction of NR4A1 also occurs in response to apoptosis inducing factors in cancer cells. When translocated to mitochondria NR4A1 binds BCL-2, thereby inducing apoptotic cell death and during apoptosis in thymocytes mitochondrial targeting of NR4A3 was observed. In B76 cells, the majority of the NR4A3 protein was located in the cytosol. Two main changes in intracellular distribution were observed. MOC31PE or CsA shifted the protein to the mitochondrial fraction compatible with induction of apoptosis. Especially in MOC31PE + CsA treated cells increased NR4A3 was detected in the nuclear fraction. Increased amount of 60 kDa protein points to increased transcription of its target genes. Since increased 55 kDa protein in the nuclear fraction was accompanied by increased mitochondrial marker protein, and the nuclear fraction was pelleted at low speed, this implies that the mitochondrial mass has increased or that mitochondria have fused to larger structures. This is most likely an effect of the ongoing cell death. The increase in NR4A3 transcript, signals a need for NR4A3 protein synthesis. No corresponding increased NR4A3 protein was detected as IT inhibits protein synthesis, but translocation of NR4A3 to mitochondria enriched fractions suggests a role for this protein in MOC31PE-induced cell-death.
In summary, these results show that a PE-containing IT, MOC31PE, induces transcription of mRNAs for genes involved in angiogenesis and tumor metastasis. In addition, the therapeutic use of MOC31PE alone or in combination with CsA may provide an approach to the treatment of recurrent/chemoresistant ovarian carcinoma, but further investigation is needed to elucidate the effect of MOC31PE and CsA in ovarian cancer models in vivo.
We are grateful for the financial support from the Inger and John Fredriksen Foundation for Ovarian Cancer Research. This project has also financially been supported by the Norwegian ExtraFoundation for Health and Rehabilitation through EXTRA funds and the Norwegian Research Council.
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al.: Phase III trial of carboplatin and paclitaxel compared With cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003, 21: 3194–3200. 10.1200/JCO.2003.02.153View ArticlePubMedGoogle Scholar
- Bamias A, Pignata S, Pujade-Lauraine E: Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol/Hematol 2012, 84: 314–326. 10.1016/j.critrevonc.2012.04.002View ArticleGoogle Scholar
- Patriarca C, Macchi RM, Marschner AK, Mellstedt H: Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2011, 38: 68–75.View ArticlePubMedGoogle Scholar
- Tveito S, Andersen K, Karesen R, Fodstad O: Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res 2011, 13: R75. 10.1186/bcr2922PubMed CentralView ArticlePubMedGoogle Scholar
- Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al.: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5: 1749–1759.View ArticleGoogle Scholar
- Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, et al.: Comparison of expression profiles in ovarian epithelium In Vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS ONE 2011, 6: e17617. 10.1371/journal.pone.0017617PubMed CentralView ArticlePubMedGoogle Scholar
- Risberg K, Fodstad Ø, Andersson Y: Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells. J Immunother 2010, 33: 272–278. 10.1097/CJI.0b013e3181c54991View ArticlePubMedGoogle Scholar
- Andersson Y, Engebraaten O, Fodstad O: Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer 2009, 101: 1307–1315. 10.1038/sj.bjc.6605312PubMed CentralView ArticlePubMedGoogle Scholar
- Xavier M: Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 2004, 77: 354–362. 10.1016/j.athoracsur.2003.07.006View ArticleGoogle Scholar
- Obchoei S, Wongkhan S, Wongkham C, Li M, Yao Q, Chen C: Cyclophilin A: potential functions and therapeuti target for human cancer. Med Sci Monit 2009, 15: RA221-RA232.PubMedGoogle Scholar
- Morgan RJJ, Synold T, Gandara D, Muggia F, Scudder S, Reed E, et al.: Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California cancer consortium trial. Int J Gynecol Cancer 2007, 17: 373–378. 10.1111/j.1525-1438.2007.00787.xView ArticlePubMedGoogle Scholar
- Sood A, Sorosky J, Squatrito R, Skilling J, Anderson B, Buller R: Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia 1999, 1: 118–122. 10.1038/sj.neo.7900019PubMed CentralView ArticlePubMedGoogle Scholar
- Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, et al.: Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 1996, 67: 826–830. 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#View ArticlePubMedGoogle Scholar
- Buick RN, Pullano R, Trent JM: Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985, 45: 3668–3676.PubMedGoogle Scholar
- Myklebust AT, Beiske K, Pharo A, Davies CL, Aamdahl S, Fodstad Ø: Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis. Br J Cancer 1991, 63: 49–53.Google Scholar
- Engebraaten O, Sivam G, Juell S, Fodstad Ø: Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 2000, 88: 970–976. 10.1002/1097-0215(20001215)88:6<970::AID-IJC21>3.0.CO;2-QView ArticlePubMedGoogle Scholar
- Andersson Y, Le H, Juell S, Fodstad Ø: AMP-activated protein kinase protects against ant-epidermal growth factor recetor-pseudomonas exotoxin A immunotoxin-induced MA11breast cancer cell death. Mol Cancer Res 2006, 5: 1050–1059.Google Scholar
- Arwert EN, Hoste E, Watt FM: Epithelial stem cells, wound healing and cancer. Nat Rev Cancer 2012, 12: 170–180. 10.1038/nrc3217View ArticlePubMedGoogle Scholar
- Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Fodstad Ø, Hergenrother PJ, et al.: Triphenylmethyl derivatived enhances the anticancer effect of immunotoxins. J Immunother 2011, 34: 438–447. 10.1097/CJI.0b013e31821e00aeView ArticlePubMedGoogle Scholar
- Chambers S, Chambers J, Davis C, Kohorn E, Schwartz P, Lorber M, et al.: Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 1997, 15: 1945–1952.PubMedGoogle Scholar
- Ben-Hamo R, Efroni S: Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol 2012, 6: 3. 10.1186/1752-0509-6-3PubMed CentralView ArticlePubMedGoogle Scholar
- Itamochi H: Targeted therapies in epithelial ovarian cancer: molecular mechanism of action. World J Biol Chem 2010, 1: 209–2200. 10.4331/wjbc.v1.i7.209PubMed CentralView ArticlePubMedGoogle Scholar
- Bell-McGuinn K, Konner J, Tew W, Spriggs DR: New drugs for ovarian cancer. Ann Oncol 2011, 22: viii77-viii82.View ArticlePubMedGoogle Scholar
- Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al.: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci 1990, 87: 6624–6628. 10.1073/pnas.87.17.6624PubMed CentralView ArticlePubMedGoogle Scholar
- Kazerounian S, Yee KO, Lawler J: Thrombospondins in cancer. Cell Mol Life Sci 2008, 65: 700–712. 10.1007/s00018-007-7486-zPubMed CentralView ArticlePubMedGoogle Scholar
- Combs MD, Braitsch CM, Lange AW, James JF, Yutzey KE: NFATC1 promotes epicardium-derived cell invasion into myocardium. Dev 2011, 138: 1747–1757. 10.1242/dev.060996View ArticleGoogle Scholar
- Cristillo AD, Bierer BE: Regulation of CXCR4 expression in human T lymphocytes by calcium and calcineurin. Mol Immunol 2003, 40: 539–553. 10.1016/S0161-5890(03)00169-XView ArticlePubMedGoogle Scholar
- Hata K, Dhar DK, Watanabe Y, Nakai H, Hoshiai H: Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. Eur J Cancer 2007, 43: 1452–1459. 10.1016/j.ejca.2007.03.004View ArticlePubMedGoogle Scholar
- Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, et al.: KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 2011, 30: 3163–3173. 10.1038/onc.2011.39PubMed CentralView ArticlePubMedGoogle Scholar
- Pearen MA, Muscat GEO: Minireview: nuclear hormone receptor 4A signaling: implications for metabolic disease. Mol Endocrinol 2010, 24: 1891–1903. 10.1210/me.2010-0015View ArticlePubMedGoogle Scholar
- Moll U, Marchenko M, Zhang X: p53 and Nurr77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 2006, 25: 4725–4743. 10.1038/sj.onc.1209601View ArticlePubMedGoogle Scholar
- Mullican S, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, et al.: Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 2007, 13: 730–735. 10.1038/nm1579View ArticlePubMedGoogle Scholar
- Thompson J, Burger ML, Whang H, Winoto A: Protein kinase C regulates mitochondrial targeting of Nur77 and its family member Nor-1 in thymocytes undergoing apoptosis. Eur J Immunol 2010, 40: 2041–2049. 10.1002/eji.200940231PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.